Procedures
Patients in the Aggrenox group received Aggrenox (dipyridamole ER 200mg and aspirin 25mg), 2 times daily for a total of 2 weeks along with the SOC treatment. Standard of care treatment consisted of an intravenous Remidesivir 200 mg loading dose and then 100 mg daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients were discharged before 10 days, they were prescribed oral decadron 6 mg daily to complete the course of 10 days. Patients in the control group only received SOC treatment as described above. No patients enrolled in this study received other experimental antivirals or immunomodulators used for COVID-19. Thus, regardless of randomization, all patients were treated according to the SOC protocol at the time of the study for COVID-19 according to the state of New Jersey.Follow-up visits were completed through phone-calls on day 14